error_outline You can access the new MDPI.com website here. Explore and share your feedback with us.
 
 
cancers-logo

Journal Browser

Journal Browser

Molecular and Clinical Challenges in Metastatic and Oligometastatic Genitourinary Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: 11 May 2026 | Viewed by 73

Special Issue Editor


E-Mail Website
Guest Editor
1. Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia
2. Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, VIC 3084, Australia
Interests: benign prostatic hyperplasia (BPH); complex stone surgery; focal therapy for prostate cancer; laparoscopic surgery; laser and lithotripsy; laser surgery for BPH including greenlight and HOLEP; robotic urology; stone disease

Special Issue Information

Dear Colleagues,

Metastatic and oligometastatic genitourinary cancers – including bladder, prostate, kidney, testicular, and penile – remain a leading cause of cancer mortality worldwide. Advances in molecular medicine, imaging, and metastasis-directed therapies have redefined our understanding of metastatic progression. Yet, diagnoses and treatment remain inconsistent, and the biological mechanism underlying the transition between localized, oligometastatic, and polymetastatic disease states remains poorly characterized.

We are pleased to invite you to contribute to this Cancers Special Issue, “Molecular and Clinical Challenges in Metastatic and Oligometastatic Genitourinary Cancers”. This collection will highlight translational and clinical research that bridges tumour biology with evolving therapeutic strategies, aligning with the journal’s scope of integrating basic science with oncology practice.

This Special Issue aims to advance the understanding of metastatic evolution in genitourinary malignancies and potential avenues of therapeutic intervention.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • Molecular and genomic profiling of genitourinary malignancies;
  • Liquid biopsies, circulating tumour DNA, and biomarkers of minimal residual disease;
  • PET, MRI, and radiomics in staging and response assessment;
  • Emerging systemic and local therapies;
  • Mechanisms of tumour microenvironment adaptation and resistance.

I look forward to receiving your contributions.

Dr. Marlon Perera
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genitourinary cancers
  • oligometastatic disease
  • metastasis-directed therapy
  • precision oncology
  • molecular profiling
  • biomarkers
  • liquid biopsy
  • tumour microenvironment
  • imaging and radiomics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 604 KB  
Review
Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies
by Kieran Sandhu, David T. Hopkins, Matilda Newton, Niranjan Sathianathen, Sachin Perera, Nathan Lawrentschuk, Declan Murphy and Marlon Perera
Cancers 2026, 18(2), 189; https://doi.org/10.3390/cancers18020189 - 7 Jan 2026
Abstract
Background: Oligometastatic bladder cancer (OMBC) is increasingly recognised as an intermediate state between localised and widespread metastatic disease, although its definition and optimal management remain uncertain. Patients with OMBC have a generally more favourable prognosis compared to patients with metastatic disease. However, [...] Read more.
Background: Oligometastatic bladder cancer (OMBC) is increasingly recognised as an intermediate state between localised and widespread metastatic disease, although its definition and optimal management remain uncertain. Patients with OMBC have a generally more favourable prognosis compared to patients with metastatic disease. However, its definition, diagnostic criteria, and optimal management remain poorly standardised. Methods: This narrative review summarises current evidence on the definitions, diagnostic approaches, and treatment strategies for OMBC, with an emphasis on emerging biological and molecular insights that may refine disease classification and guide therapy. Results: Existing definitions of OMBC rely on lesion count and anatomical distribution, overlooking molecular and clinicopathological heterogeneity that influences prognosis and treatment response. Advances in Positron Emission Tomography (PET)/Computed Tomography (CT) and magnetic resonance imaging (MRI) have improved detection of small-volume disease, while liquid biopsy and circulating tumour DNA show promise for assessing micrometastatic burden. Therapeutic approaches, including metastasis-directed and consolidative therapies, are under investigation. Nonetheless, most data are derived from small, retrospective series, and evidence from prospective studies remains limited. Conclusions: Prospective, biomarker-integrated, and randomised trials are essential to refine definitions, optimise patient selection for therapy, and define the role of precision-based multimodal therapy in OMBC management. Full article
Show Figures

Figure 1

Back to TopTop